 |
|
|
ALKS Description — Alkermes plc
Alkermes is a biopharmaceutical company. Co. has a portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO, which utilizes Co.'s proprietary LinkeRx and NanoCrystal technologies; and LYBALVI, which is an oral atypical antipsychotic drug approved in the U.S. for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder.
| Company Name: |
Alkermes plc |
| Website: |
www.alkermes.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding ALKS: |
57 |
| Total Market Value Held by ETFs: |
$1,045,831,901.55 |
| Total Market Capitalization: |
$4,027,000,000 |
| % of Market Cap. Held by ETFs: |
25.97% |
|
| ETF |
ALKS Weight |
ALKS Amount |
| IJR |
0.34% |
$271,931,868 |
| VTI |
0.01% |
$126,755,759 |
| VB |
0.07% |
$103,384,621 |
| IWM |
0.15% |
$94,398,086 |
| VXF |
0.06% |
$60,559,243 |
| XBI |
0.90% |
$60,150,050 |
| VBK |
0.17% |
$58,531,981 |
| FBT |
3.29% |
$36,751,134 |
| SPSM |
0.34% |
$35,822,219 |
| IWO |
0.31% |
$33,968,367 |
| List of all 57 ETFs holding ALKS
» |
|
|
|
|
|
Buy (2.92 out of 4)
22nd percentile
|
PARTNER NEWS:Thu, May 2, 9:39 AM, Zacks
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
Alkermes (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
Mon, Apr 22, 12:14 PM, Zacks
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
|
|
Free ALKS Email Alerts:
